Lecanemab, an experimental drug for the treatment of Alzheimer’s disease, has received marketing authorization in the United States under the name Leqembi. How effective is it? Its side effects? Will it arrive in France? Summary [Mise à jour le 13 janvier 2023 à 9h48] On January 6, 2023, the American drug agency FDA (Food and Drug Administration) … Read more
They have been published New Enlgand Journal of Medicine the expected results of the experimentation of lecanemab, a new drug that would slow down the cognitive decline in patients with Alzheimer when administered in the early stages of the disease. It is a monoclonal antibody, developed by Eisai and Biogen, aimed against the amyloid beta … Read more
© Getty Images/iStockphoto Alzheimer’s disease is still treatable. This is evident from study results of pharmaceutical companies Eisai and Biogen, who jointly developed the new drug lecanemab. Especially in an early stage, patients would benefit from it. But it’s not all good news: there are concerns about side effects, and the question remains whether patients … Read more
At stake is a drug that managed to delay cognitive decline in the early stages of the disease Many consider the disease of Alzheimer the next pandemic, and so far, no drug has seemed to slow the disease. But an experimental drug managed to delay cognitive decline at an early stage of the disease, advances … Read more
Lecanemab, the first drug that slows the destruction of the brain in the case of Alzheimer’s disease, has been declared a historic and important success, writes the BBC.The discovery ends decades of failures and shows that a new era of drugs to treat Alzheimer’s – the most common form of dementia – is possible.However, the … Read more
Wednesday, November 30, 2022, 10:35 a.m 142 readings Lecanemab, the first drug that slows the destruction of the brain in the case of Alzheimer’s disease, has been declared a historic and important success, writes the BBC.The discovery ends decades of failures and shows that a new era of drugs to treat Alzheimer’s – the most … Read more